Peptide
Cartalax
SaveA Khavinson bioregulator tripeptide (Ala-Glu-Asp) studied for cartilage and musculoskeletal tissue support and potential geroprotective effects.
Quick verdict
Very limited data outside Russian bioregulator research. No international trials or regulatory approvals.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Small Russian studies suggest effects on cartilage gene expression and possible lifespan extension in animal models. Not replicated internationally.
Benefits
- Claimed cartilage-protective properties
- Possible geroprotective effects in animal models
Dosage notes
Russian protocols: 5–10 mg/day orally for 10–30 day courses.
Side effects
- Not well characterized
- GI discomfort possible
Who should be cautious
Not approved outside Russia. Product authenticity and purity are hard to verify.
What this page cannot tell you
Evidence is confined to Russian-language publications from a single research group.
Leaderboard scores
- Recovery15
- Longevity15
Write a review
Sign in to write a review.